Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell
carcinoma, but some patients do not respond or need dose reductions due to toxicity …

Background: Currently, sunitinib represents one of the therapeutic strongholds for renal cell
carcinoma, but the criteria for treatment selection are lacking. We assessed the role of …

Background. There are no validated markers that predict outcome in metastatic renal cell
cancer (mRCC) patients treated with sunitinib. Recently, single nucleotide polymorphism …

Background In our exploratory studies, we associated single nucleotide polymorphisms
(SNPs) in candidate genes with the efficacy and toxicities of sunitinib in metastatic renal cell …

Background: There are no validated markers that predict response in metastatic renal cell
cancer (RCC) patients treated with sunitinib. We aim to study the impact of single-nucleotide …

Purpose Sunitinib is a first-line advanced renal cell carcinoma (RCC) standard of care. In a
randomized phase II trial comparing sunitinib treatment schedules, separate exploratory …

Purpose: The objective of this study was to identify genetic polymorphisms related to the
pharmacokinetics and pharmacodynamics of sunitinib that are associated with a prolonged …

PURPOSE: Biomarkers that predict response or toxicity to antiangiogenic therapy are sought
to favorably inform the risk/benefit ratio. This study evaluated the association of vascular …

Background Previous studies suggest that expression of hypoxia markers may be
associated with response to antiangiogenic drugs. Thus, we aimed to identify predictors of …

Purpose The aim of this study was to investigate the pharmacogenetic determinants of
sunitinib-related toxicity and ethnic difference in metastatic renal cell carcinoma (mRCC) …